<p>GeneDx 控股公司（NASDAQ：WGS - 获取免费报告）的股价在周一交易前出现下跌，此前一位内部人士出售了公司股票。该股票先前收盘价为 30.07 美元，但开盘价为 25.85 美元。GeneDx 股票最后交易价为 27.23 美元，成交量为 25,870 股。具体来说，Casdin Capital 董事会购买了 50,000 股 GeneDx 股票，交易日期为 5 月 13 日星期一。股票平均购买价为 23.31 美元/股，总交易额为 1,165,500.00 美元。购买完成后，该董事现直接持有公司股票 2,753,509 股，价值 64,184,294.79 美元。这一收购交易已在提交给美国证券交易委员会（SEC）的法律文件中披露，可通过此超链接查看。此外，首席执行官 Katherine Stueland 于 6 月 10 日星期一出售了 2,652 股股票。股票平均售价为 24.92 美元，总交易额为 66,087.84 美元。出售后，首席执行官现持有公司股票 79,763 股，价值约 1,987,693.96 美元。此次出售已在提交给证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，Casdin Capital 董事会于 5 月 13 日星期一购买了 50,000 股 GeneDx 股票。股票平均购买价为 23.31 美元/股，总价值为 1,165,500.00 美元。收购完成后，该董事现直接持有公司 2,753,509 股股票，价值 64,184,294.79 美元。关于此次收购的披露可在此处找到。过去 90 天内，内部人士已购买了价值 3,771,670 美元的 175,804 股公司股票，并出售了价值 15,701,354 美元的 490,343 股股票。公司内部人士持有公司股份的比例为 28.10%。</p>
<h2>华尔街分析师观点</h2>
<p>一些分析师最近对该股发表了意见。高盛集团将 GeneDx 股票的目标价从 28.00 美元上调至 32.00 美元，并在 7 月 31 日星期三的一份报告中给予该股 “中性” 评级。Jefferies 金融集团于 6 月 3 日星期一开始对 GeneDx 进行覆盖。他们给出了一份 “持有” 评级，并对该股设定了 21.00 美元的价格目标。Craig Hallum 将 GeneDx 的目标价从 43.00 美元上调至 46.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该股 “买入” 评级。TD Cowen 将 GeneDx 的目标价从 46.00 美元上调至 50.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该股 “买入” 评级。最后，BTIG 研究将 GeneDx 的价格目标从 35.00 美元上调至 45.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该公司 “买入” 评级。两位分析师对该股进行了持有评级，另外三位对该公司股票发出了买入评级。根据 MarketBeat 的数据，GeneDx 目前的共识评级为 “中等买入”，目标价为 38.80 美元。</p>
<p><strong>获取我们关于 GeneDx 的最新股票报告</strong></p>
<h2>GeneDx 股价下跌 5.3%</h2>
<p>该公司的资产负债比为 0.27，流动比率为 2.38，速动比率为 2.99。股票的 50 天移动平均价为 28.43 美元，200 天移动平均价为 16.70 美元。该公司的市值为 7.4364 亿美元，市盈率为-5.81，β系数为 2.29。</p>
<h2>对 GeneDx 的对冲基金观点</h2>
<p>一些机构投资者最近调整了他们对该公司的持股。Rhumbline Advisors 在第二季度将其持有的 GeneDx 股票份额增加了 8096.4%。Rhumbline Advisors 现在拥有 18,360 股公司股票，价值 480,000 美元，较之前增加了 18,136 股。nVerses Capital LLC 在第二季度购买了一份 GeneDx 的新头寸，价值 5 万美元。纽约梅隆银行在第二季度购买了 GeneDx 的新头寸，价值 991,000 美元。Calamos Advisors LLC 在第二季度购买了一份 GeneDx 的新头寸，价值约 1,137,000 美元。最后，Assenagon Asset Management S.A.在第二季度购买了 GeneDx 的新头寸，价值约 9,575,000 美元。目前 61.72% 的股份由机构投资者持有。</p>
<h2>关于 GeneDx（获取免费报告）</h2>
<p>GeneDx 控股公司及其子公司提供基因组相关的诊断和信息服务。该公司提供 Centrellis，一款人工智能驱动的健康智能平台，整合了数字工具和人工智能，使科学家能够摄取和综合临床和基因组数据，提供全面的健康见解。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 GeneDx 更好</li>
<li>投资大市值股票：深入大市值股票</li>
<li>Newmont 股票：在全球最大黄金矿商中占一席之地</li>
<li>交易停牌解释</li>
<li>PulteGroup 在市场崩盘期间回购 15 亿美元股票</li>
<li>股票情绪分析：工作原理</li>
<li>经济衰退为何再次出现及对股市意味着什么</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 时间不多了-6 月 25 日截止日期即将到来！（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx"/></p>
<h2>您现在是否应该投资 1,000 美元购买 GeneDx 股票？</h2>
<p>在考虑 GeneDx 之前，您可能会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 GeneDx 不在这份名单上。</p>
<p>尽管 GeneDx 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

信息服务集团

<p>GeneDx 控股公司（NASDAQ：WGS）股价在一位内部人士出售股份后出现了跳空下跌。该董事以每股平均价格 23.31 美元购买了 50,000 股股份。在过去三个月内，内部人士买入了 175,804 股股份，卖出了 490,343 股股份。分析师们给予 GeneDx 一项 “中等买入” 评级，并设定了 38.80 美元的共识目标价。该公司提供基因组相关的诊断和信息服务</p>

<p>GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $30.07, but opened at $25.85. GeneDx shares last traded at $27.23, with a volume of 25,870 shares. Specifically, Director Casdin Capital, Llc bought 50,000 shares of GeneDx stock in a transaction dated Monday, May 13th. The stock was purchased at an average price of $23.31 per share, for a total transaction of $1,165,500.00. Following the completion of the purchase, the director now directly owns 2,753,509 shares of the company's stock, valued at $64,184,294.79. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Katherine Stueland sold 2,652 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $24.92, for a total transaction of $66,087.84. Following the sale, the chief executive officer now owns 79,763 shares of the company's stock, valued at approximately $1,987,693.96. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Casdin Capital, Llc bought 50,000 shares of GeneDx stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $23.31 per share, with a total value of $1,165,500.00. Following the acquisition, the director now directly owns 2,753,509 shares in the company, valued at $64,184,294.79. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 175,804 shares of company stock worth $3,771,670 and have sold 490,343 shares worth $15,701,354. Corporate insiders own 28.10% of the company's stock.</p>
<div class="lb-trans"><p>GeneDx 控股公司（NASDAQ：WGS - 获取免费报告）的股价在周一交易前出现下跌，此前一位内部人士出售了公司股票。该股票先前收盘价为 30.07 美元，但开盘价为 25.85 美元。GeneDx 股票最后交易价为 27.23 美元，成交量为 25,870 股。具体来说，Casdin Capital 董事会购买了 50,000 股 GeneDx 股票，交易日期为 5 月 13 日星期一。股票平均购买价为 23.31 美元/股，总交易额为 1,165,500.00 美元。购买完成后，该董事现直接持有公司股票 2,753,509 股，价值 64,184,294.79 美元。这一收购交易已在提交给美国证券交易委员会（SEC）的法律文件中披露，可通过此超链接查看。此外，首席执行官 Katherine Stueland 于 6 月 10 日星期一出售了 2,652 股股票。股票平均售价为 24.92 美元，总交易额为 66,087.84 美元。出售后，首席执行官现持有公司股票 79,763 股，价值约 1,987,693.96 美元。此次出售已在提交给证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，Casdin Capital 董事会于 5 月 13 日星期一购买了 50,000 股 GeneDx 股票。股票平均购买价为 23.31 美元/股，总价值为 1,165,500.00 美元。收购完成后，该董事现直接持有公司 2,753,509 股股票，价值 64,184,294.79 美元。关于此次收购的披露可在此处找到。过去 90 天内，内部人士已购买了价值 3,771,670 美元的 175,804 股公司股票，并出售了价值 15,701,354 美元的 490,343 股股票。公司内部人士持有公司股份的比例为 28.10%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts recently weighed in on the stock. The Goldman Sachs Group upped their target price on shares of GeneDx from $28.00 to $32.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, July 31st. Jefferies Financial Group initiated coverage on GeneDx in a research report on Monday, June 3rd. They issued a &#34;hold&#34; rating and a $21.00 price objective on the stock. Craig Hallum boosted their target price on GeneDx from $43.00 to $46.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, July 31st. TD Cowen upped their target price on GeneDx from $46.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, July 31st. Finally, BTIG Research lifted their price target on GeneDx from $35.00 to $45.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, GeneDx presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $38.80.</p>
<div class="lb-trans"><p>一些分析师最近对该股发表了意见。高盛集团将 GeneDx 股票的目标价从 28.00 美元上调至 32.00 美元，并在 7 月 31 日星期三的一份报告中给予该股 “中性” 评级。Jefferies 金融集团于 6 月 3 日星期一开始对 GeneDx 进行覆盖。他们给出了一份 “持有” 评级，并对该股设定了 21.00 美元的价格目标。Craig Hallum 将 GeneDx 的目标价从 43.00 美元上调至 46.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该股 “买入” 评级。TD Cowen 将 GeneDx 的目标价从 46.00 美元上调至 50.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该股 “买入” 评级。最后，BTIG 研究将 GeneDx 的价格目标从 35.00 美元上调至 45.00 美元，并在 7 月 31 日星期三的一份研究报告中给予该公司 “买入” 评级。两位分析师对该股进行了持有评级，另外三位对该公司股票发出了买入评级。根据 MarketBeat 的数据，GeneDx 目前的共识评级为 “中等买入”，目标价为 38.80 美元。</p>
</div><p><strong>Get Our Latest Stock Report on GeneDx</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 GeneDx 的最新股票报告</strong></p>
</div><h2>GeneDx Trading Down 5.3 %</h2>
<div class="lb-trans"><h2>GeneDx 股价下跌 5.3%</h2>
</div><p>The company has a debt-to-equity ratio of 0.27, a current ratio of 2.38 and a quick ratio of 2.99. The stock has a 50 day moving average of $28.43 and a 200 day moving average of $16.70. The firm has a market cap of $743.64 million, a P/E ratio of -5.81 and a beta of 2.29.</p>
<div class="lb-trans"><p>该公司的资产负债比为 0.27，流动比率为 2.38，速动比率为 2.99。股票的 50 天移动平均价为 28.43 美元，200 天移动平均价为 16.70 美元。该公司的市值为 7.4364 亿美元，市盈率为-5.81，β系数为 2.29。</p>
</div><h2>Hedge Funds Weigh In On GeneDx</h2>
<div class="lb-trans"><h2>对 GeneDx 的对冲基金观点</h2>
</div><p>Several institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in shares of GeneDx by 8,096.4% in the 2nd quarter. Rhumbline Advisers now owns 18,360 shares of the company's stock valued at $480,000 after purchasing an additional 18,136 shares during the period. nVerses Capital LLC purchased a new position in GeneDx during the second quarter valued at $50,000. Bank of New York Mellon Corp bought a new stake in shares of GeneDx during the 2nd quarter valued at $991,000. Calamos Advisors LLC purchased a new position in GeneDx during the 2nd quarter valued at about $1,137,000. Finally, Assenagon Asset Management S.A. purchased a new stake in GeneDx in the second quarter worth about $9,575,000. 61.72% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了他们对该公司的持股。Rhumbline Advisors 在第二季度将其持有的 GeneDx 股票份额增加了 8096.4%。Rhumbline Advisors 现在拥有 18,360 股公司股票，价值 480,000 美元，较之前增加了 18,136 股。nVerses Capital LLC 在第二季度购买了一份 GeneDx 的新头寸，价值 5 万美元。纽约梅隆银行在第二季度购买了 GeneDx 的新头寸，价值 991,000 美元。Calamos Advisors LLC 在第二季度购买了一份 GeneDx 的新头寸，价值约 1,137,000 美元。最后，Assenagon Asset Management S.A.在第二季度购买了 GeneDx 的新头寸，价值约 9,575,000 美元。目前 61.72% 的股份由机构投资者持有。</p>
</div><h2>About GeneDx (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 GeneDx（获取免费报告）</h2>
</div><p>GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.</p>
<div class="lb-trans"><p>GeneDx 控股公司及其子公司提供基因组相关的诊断和信息服务。该公司提供 Centrellis，一款人工智能驱动的健康智能平台，整合了数字工具和人工智能，使科学家能够摄取和综合临床和基因组数据，提供全面的健康见解。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than GeneDx</li>
<li>Investing in large cap stocks: Diving into big caps</li>
<li>Newmont Stock: Stake a Claim in the World’s Largest Gold Miner</li>
<li>Trading Halts Explained</li>
<li>PulteGroup is Buying Back $1.5 Billion in Stock During a Crash</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Why a Recession is Back in Play and What it Means for Stocks</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 GeneDx 更好</li>
<li>投资大市值股票：深入大市值股票</li>
<li>Newmont 股票：在全球最大黄金矿商中占一席之地</li>
<li>交易停牌解释</li>
<li>PulteGroup 在市场崩盘期间回购 15 亿美元股票</li>
<li>股票情绪分析：工作原理</li>
<li>经济衰退为何再次出现及对股市意味着什么</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 时间不多了-6 月 25 日截止日期即将到来！（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9011&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in GeneDx right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 GeneDx 股票？</h2>
</div><p>Before you consider GeneDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GeneDx 之前，您可能会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 GeneDx 不在这份名单上。</p>
</div><p>While GeneDx currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 GeneDx 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

GeneDx（纳斯达克代码：WGS）股价在内部人士抛售后跳空下跌